Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

Figure 3 Treatment efficacy of all patients based on the groups divided by carbohydrate antigen 19-9 ratio and tumor size ratio. A: Treatment efficacy based on the groups divided by carbohydrate antigen 19-9 ratio (CR); B: Treatment efficacy based on the groups divided by tumor size ratio (TR); C: Multivariable analysis showed that CR and TR of neoadjuvant therapy were associated with increased odds of achieving a complete or near-complete pathologic response. AJCC: American Joint Committee on Cancer; BMI: Body mass index; PD: Progressive disease; SD: Stable disease.